TY - JOUR
T1 - Posttransplantation lymphoproliferative disorders treated with cyclophosphamide‐doxorubicin‐vincristine‐prednisone chemotherapy
AU - Garrett, T. J.
AU - Drusin, Ronald E.
AU - Schulman, Larry L.
AU - Reison, Dennis S.
AU - Chadburn, Amy
AU - Knowles, Daniel M.
AU - Barr, Mark L.
AU - Chen, Jonathan M.
AU - Smith, Craig R.
AU - Rose, Eric A.
AU - Michler, Robert E.
PY - 1993/11/1
Y1 - 1993/11/1
N2 - Background. Posttransplantation lymphoproliferative disorders after solid organ transplantation are a serious complication occurring in 1–10% of patients. Different therapies have been used, but the optimal treatment is unknown. There is relatively little information in the literature on the experience with cytotoxic chemotherapy. Methods. The disease stage of patients with biopsydocumented posttransplantation lymphoproliferative was determined with standard methods to establish the extent of the disease. Patients in whom the disease failed to regress after initial management, which included reduction in immunosuppression, were treated with a combination chemotherapy regimen consisting of six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Response to therapy was determined by following previously defined sites of disease with appropriate tests. Patients were maintained on a reduced dose of immunosuppressants. Results. In the four patients studied, lymphoproliferative disorders developed after heart (three cases) or lung (one case) transplantation, which did not regress after immunosuppression was reduced. All four experienced a complete remission with CHOP chemotherapy, which continued at 3, 13+, 20 and 30+ months after completion of treatment. One patient died of sepsis after completing therapy at a point when his leukocyte count was normal, and no evidence of posttransplantation lymphoproliferative disorder was found at autopsy. A second patient died of liver failure with no clinical evidence of lymphoproliferative disorder. Conclusion. Although this is a small series, it demonstrates that patients with posttransplantation lymphoproliferative disorders may respond to cytotoxic chemotherapy. The duration of response is undetermined.
AB - Background. Posttransplantation lymphoproliferative disorders after solid organ transplantation are a serious complication occurring in 1–10% of patients. Different therapies have been used, but the optimal treatment is unknown. There is relatively little information in the literature on the experience with cytotoxic chemotherapy. Methods. The disease stage of patients with biopsydocumented posttransplantation lymphoproliferative was determined with standard methods to establish the extent of the disease. Patients in whom the disease failed to regress after initial management, which included reduction in immunosuppression, were treated with a combination chemotherapy regimen consisting of six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Response to therapy was determined by following previously defined sites of disease with appropriate tests. Patients were maintained on a reduced dose of immunosuppressants. Results. In the four patients studied, lymphoproliferative disorders developed after heart (three cases) or lung (one case) transplantation, which did not regress after immunosuppression was reduced. All four experienced a complete remission with CHOP chemotherapy, which continued at 3, 13+, 20 and 30+ months after completion of treatment. One patient died of sepsis after completing therapy at a point when his leukocyte count was normal, and no evidence of posttransplantation lymphoproliferative disorder was found at autopsy. A second patient died of liver failure with no clinical evidence of lymphoproliferative disorder. Conclusion. Although this is a small series, it demonstrates that patients with posttransplantation lymphoproliferative disorders may respond to cytotoxic chemotherapy. The duration of response is undetermined.
KW - cardiac transplantation
KW - immunosuppressive therapy
KW - lung transplantation
KW - non‐Hodgkin lymphoma
KW - posttransplantation lymphoproliferative disorders
UR - http://www.scopus.com/inward/record.url?scp=0027432328&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027432328&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19931101)72:9<2782::AID-CNCR2820720941>3.0.CO;2-H
DO - 10.1002/1097-0142(19931101)72:9<2782::AID-CNCR2820720941>3.0.CO;2-H
M3 - Article
C2 - 8402504
AN - SCOPUS:0027432328
SN - 0008-543X
VL - 72
SP - 2782
EP - 2785
JO - Cancer
JF - Cancer
IS - 9
ER -